The Effect of Vitamin C on Quality of Life of Terminal Cancer Patients

This study determines whether high dose vitamin C is effective for quality of life in terminal cancer patients.

The investigator's project is a single medical center, randomized double- blinded trial. The target group is terminal cancer patients at Palliative care clinics. The experimental group will receive intravenous high-dose vitamin C 30 g in 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment. The control group will receive 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment. The primary outcome is the improvement of quality of life, measured by European Organization for Research and Treatment of cancer (EORTC). The secondary outcome is the survival analysis.The participants will be followed up weekly for 2 weeks, then bi-weekly for 6 months.

The study group will receive intravenous high-dose vitamin C 30 gm in 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.

The control group will receive 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.

QOL measured by European Organization for Research and Treatment of cancer Quality of Life Questionnaire (EORTC QLQ)-C30

Inclusion Criteria: -Terminal colon cancer patients without pleural effusions, who will not receive any curative radiotherapy or chemotherapy. Exclusion Criteria: Renal metastasis or obstructive uropathy by radiology Nephrotic syndrome Creatinine over 1.5mg/dl Urolithasis Under other folk therapy or vitamin infusion therapy Those who can't exercise the right of consent Those who can't answer the questionaires Glucose-6-Phosphate Dehydrogenase Deficiency Severe lower leg edema or general edema